Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbramson Cancer Center at Penn Medicine
About this trial
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
Eligibility criteria
Qualifiers
Pure or mixed variant urothelial carcinoma
squamous differentiation
glandular differentiation
nested pattern
Disqualifiers
Urinary diversion with an orthotopic neobladder
History of inflammatory bowel disease
Prior partial or complete small bowel obstruction either before or after radical cystectomy
Prior radiotherapy to the pelvis;
Trial design
Treatments tested in this trial
- Concurrent Immunotherapy and Radiation Therapy
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov